Market cap
$376 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
9.1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -76.63 | -- | -- |
| EBIT | -23.23 | -22.88 | -6.39 | -32.38 | -- |
| Net Profit | -18.96 | -25.61 | -9.93 | -29.15 | -- |
| EPS | -15.09 | -7.00 | 1.39 | -1.25 | -- |
| Book Value | -- | -- | -42.56 | -19.30 | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-24 | Dec-23 |
| EBIT-Margin
| -- | -- | -21,199.78 | -- | -- |
| Net Margin
| -11,697.06 | -- | -20,390.49 | -- | -- |
| Return on equity
| -63.97 | -- | -163.28 | -89.69 | -54.13 |
| Return on Capital
| -59.39 | -- | -- | -78.49 | -51.75 |
| Return on Assets
| -52.78 | -- | -76.79 | -65.18 | -48.43 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.18 | 0.12 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
|
--
|
-78.49
|
-51.75
|
-47.92
|
-132.78
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-163.28
Lower than Peers by 122.95
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
|
-163.28
|
-89.69
|
-54.13
|
-48.10
|
-134.71
|
|
Peer Median
|
-40.33
|
--
|
--
|
--
|
--
|
ROA
-76.79
Lower than Peers by 45.55
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
|
-76.79
|
-65.18
|
-48.43
|
-44.73
|
-67.72
|
|
Peer Median
|
-31.24
|
--
|
--
|
--
|
--
|
EBIT Margin
-21,199.78
Lower than Peers by 21,117.18
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
|
-21,199.78
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-82.60
|
--
|
--
|
--
|
--
|
Net Margin
-20,390.49
Lower than Peers by 20,299.19
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
|
-20,390.49
|
--
|
--
|
-11,697.06
|
--
|
|
Peer Median
|
-91.30
|
--
|
--
|
--
|
--
|
Cash Profit Margin
-0.04
Lower than Peers by 0.04
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
|
-0.04
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
-76.63
Lower than Peers by 130.66
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
|
-76.63
|
--
|
--
|
--
|
--
|
|
Peer Median
|
54.03
|
--
|
--
|
--
|
--
|
EBIT Growth
-6.39
Lower than Peers by 5.37
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
|
-6.39
|
5.19
|
-29.01
|
-62.43
|
-3.11
|
|
Peer Median
|
-1.02
|
--
|
--
|
--
|
--
|
Net Profit Growth
-9.93
Lower than Peers by 2.40
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
|
-9.93
|
-1.96
|
-22.02
|
-56.58
|
-51.52
|
|
Peer Median
|
-7.53
|
--
|
--
|
--
|
--
|
EPS Growth
1.39
Lower than Peers by 12.84
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
|
1.39
|
0.05
|
-0.21
|
-0.15
|
-0.13
|
|
Peer Median
|
14.23
|
--
|
--
|
--
|
--
|
Book Value Growth
-58.79
Lower than Peers by 48.65
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
|
-58.79
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.13
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
|
--
|
0.18
|
0.12
|
0.00
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.05
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
|
0.05
|
0.01
|
0.01
|
0.00
|
0.02
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
2.06
Lower than Peers by 3.75
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
|
2.06
|
2.95
|
10.45
|
17.49
|
9.87
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
2.06
Lower than Peers by 3.64
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
|
2.06
|
--
|
--
|
16.55
|
--
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
|
--
|
--
|
--
|
-883.13
|
-0.98
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
123.45
Higher than Peers by 104.44
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
|
123.45
|
--
|
--
|
--
|
--
|
|
Peer Median
|
19.01
|
--
|
--
|
--
|
--
|
Asset Turnover
0.00
Lower than Peers by 0.06
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
|
--
|
--
|
9,664.02
|
3,817.77
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
|
--
|
1,577.51
|
1,779.56
|
1,070.25
|
2,691.20
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
|
--
|
-0.84
|
-1.59
|
-7.10
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
9.11
Higher than Peers by 3.78
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
|
9.11
|
0.99
|
1.13
|
2.54
|
--
|
|
Peer Median
|
5.33
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-3.16
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
|
-3.16
|
0.17
|
-0.31
|
-4.28
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
376
Higher than Peers by 234
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
|
376
|
--
|
--
|
--
|
--
|
|
Peer Median
|
142
|
--
|
--
|
--
|
--
|